Skip to main content

Table 1 Key characteristics of Study 1 and Study 2

From: Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients

 

Study 1

Study 2

Countries

Benin, Burkina Faso, Gabon, Tanzania

Burkina Faso, Gabon, Kenya

N (planned)

210

180

N (pursued)

123

20

Age cohorts (years)

Adults (18–65)

Teenager (12–17)

Children (7–17)

Children (2–11)a

Young children (0.5–6)a

 

Parasitemia at inclusion

Adults: >100 parasites/µL

>2000 parasites/µL

Children: >1000 parasites/µL

Severe malaria

Planned for young children cohort

No

SAR97276A treatment

1 day intramuscular 0.18 mg/kg (max. 12.5 mg)

3 days intramuscular once daily 0.5 mg/kg (max. 36 mg)

3 days intramuscular 0.18 mg/kg (max. 12.5 mg)

1 day intravenous 0.14 mg/kg (max. 10 mg)

3 days intramuscular twice daily 0.25 mg/kg per dose (max. 18 mg per dose)

Control treatment

None

Artemether–lumefantrine

  1. aThese groups were not enrolled when study was conducted